| Followers | 8 |
| Posts | 2087 |
| Boards Moderated | 0 |
| Alias Born | 07/31/2006 |
Thursday, May 27, 2010 1:11:06 PM
emisbio, here's more on the NanoViricides' RabiCide:
Here's an iHub post where you'll find a link to the PR from the original Vietnam study, as well as another link to another of my previous iHub postings, in which you'll see quotes from CEO Seymour regarding the Rabies study, and a link to an mp3 of an interview.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=32509482
Also, this past Decenber Dr. Seymour in another interview talked about studies that the CDC has been doing on the NanoViricides Rabies drug candidate, and stated the CDC has "... had very good success with a drug against Rabies". This final link is to a post with audio of that recent interview as well as selected transcriptions:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=44641790
best to all.
Here's an iHub post where you'll find a link to the PR from the original Vietnam study, as well as another link to another of my previous iHub postings, in which you'll see quotes from CEO Seymour regarding the Rabies study, and a link to an mp3 of an interview.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=32509482
Also, this past Decenber Dr. Seymour in another interview talked about studies that the CDC has been doing on the NanoViricides Rabies drug candidate, and stated the CDC has "... had very good success with a drug against Rabies". This final link is to a post with audio of that recent interview as well as selected transcriptions:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=44641790
best to all.
Recent NNVC News
- Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides • ACCESS Newswire • 04/21/2026 12:30:00 PM
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2025 09:07:54 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/29/2025 08:33:17 PM
